Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 182 ()
OP08: Long-term efficacy and pharmacodynamics of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn’s disease: the OPERA II study

ECCO '19 Copenhagen

Year: 2019
Authors:

G. D’Haens*1, W. Reinisch2, S. D. Lee3, D. Tarabar4, E. Louis5, M. Kłopocka6, J. Klaus7, S. Schreiber8, D. I. Park9, X. Hébuterne10, K. J. Gorelick11, S. W. Martin12, A. Banerjee12, P. Nagy13, Y. Wang14, F. Cataldi14, W. J. Sandborn15

1Academic Medical Centre, Amsterdam, The Netherlands, 2Medical University of Vienna, Vienna, Austria, 3University of Washington, Seattle, WA, USA, 4Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 5University Hospital of Liège, Liège, Belgium, 6Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 7University Hospital Ulm, Ulm, Germany, 8University Hospital Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany, 9Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, 10University of Nice Sophia Antipolis, Hospital l’Archet, Nice, France, 11Zymo Consulting Group, Newtown Square, PA, USA, 12Pfizer, Cambridge, MA, USA, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, USA, 15University of California San Diego, La Jolla, CA, USA

OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, Phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Peyrin-Biroulet*1, J. Panés2, M. Chiorean3, J. Zhang4, S. Vermeire5, V. Jairath6, A. Yarur7, C. Cabell4, S. Naik4, W. J. Sandborn8

1University Hospital of Nancy, Vandœuvre-lès-Nancy, France, 2Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 3Virginia Mason Medical Center, Seattle, USA, 4Arena Pharmaceuticals, Inc., San Diego, USA, 5University Hospitals Leuven, Leuven, Flanders, Belgium, 6Western University, London, Ontario, Canada, 7Medical College of Wisconsin, Milwaukee, USA, 8University of California San Diego, La Jolla, USA

OP10: Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Brooks*1,2, D. Modos3, P. Sudhakar4,5, D. Fazekas4,6, A. Zoufir3, A. Watson1,7, M. Tremelling1, B. Verstockt8, S. Vermeire8, A. Bender3, S. Carding2,7, T. Korcsmaros2,4

1Norfolk and Norwich University Hospital, Gastroenterology, Norwich, UK, 2The Quadram Institute Bioscience, Gut Microbes and Health Programs, Norwich, UK, 3Centre for Molecular Science Informatics, Department of Chemistry University of Cambridge, Cambridge, UK, 4Earlham Institute, Norwich Research Park, Norwich, UK, 5KU Leuven,, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 6Eötvös Loránd, Department of Genetics, Budapest, Hungary, 7University of East Anglia, Norwich Medical School, Norwich, UK, 8University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

OP11: Organoids derived from inflamed intestinal biopsies of patients with ulcerative colitis lose their inflammatory phenotype during ex vivo culture

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Arnauts*1,2, B. Verstockt1,3, M. Vancamelbeke1, S. Vermeire1,3, C. Verfaillie2, M. Ferrante1,3

1KU Leuven, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium, 2KU Leuven, Department of Development and Regeneration, Leuven, Belgium, 3KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

OP12: Targeting inflammation in ulcerative colitis by inhibiting glucose uptake

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Gropp*1, H. Jodeleit1, J. Caesar1, C. Villarroel Aguilera1, F. Beigel2,3, S. Breiteneicher3, J. Stallhofer3, M. Siebeck1

1Hospital of the Ludwig Maximilian University, General-, Visceral-, Vascular- and Transplantation Surgery, Munich, Germany, 2Hospital of the Ludwig Maximilian University, Laboratory Medicine, Munich, Germany, 3Hospital of the Ludwig Maximilian University, Medicine II, Munich, Germany

OP13: Molecular response to ustekinumab in moderate-to-severe ulcerative colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI Phase 3 induction study

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Li*1, F. Yang1, K. Hayden1, D. Strawn1, E. Wadman1, S. Bhagat1, C. Marano1, J. R. Friedman1

1Janssen Research and Development, LLC, Spring House, USA

OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study

ECCO '19 Copenhagen

Year: 2019
Authors:

W. J. Sandborn*1,1, S. Schreiber2, S. D. Lee3, J. O. Lindsay4, X. Hebuterne5, W. Zhou6, F. Cataldi6, A. P. Lacerda6, B. Huang6, W. Xie6, E. V. Loftus Jr7

1University of California San Diego, La Jolla, USA, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3University of Washington, Seattle, USA, 4Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK, 5Service de Gastroentérologie et Nutrition Clinique, Nice, France; Université de Nice-Sophia-Antipolis, Nice, France, 6AbbVie Inc., North Chicago, USA, 7Mayo Clinic, Rochester, USA

OP15: Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Burisch*1, H. Vardi2, D. Schwartz3, Z. Krznaric4, P. L. Lakatos5, M. Fumery6, L. Kupcinskas7, F. Magro8, E. Belousova9, P. Oksanen10, N. Arebi11, E. Langholz12, S. Turcan13, R. D’Inca14, V. Hernandez15, D. Valpiani16, Z. Vegh5, M. Giannotta17, K. H. Katsanos18, D. Duricova19, K. R. Nielsen20, H. A. L. Kievit21, P. Ellul22, R. Salupere23, A. Goldis24, I. Kaimakliotis25, N. Pedersen26, V. Andersen27, J. Halfvarson28, S. Sebastian29, J. F. Dahlerup30, P. Munkholm1, S. Odes3, Epi-IBD

1North Zealand University Hospital, Frederikssund, Denmark, 2Ben Gurion University of the Negev, Beer Sheva, Israel, 3Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel, 4University Hospital Center Zagreb, Zagreb, Croatia, 5Semmelweis University, Budapest, Hungary, 6Amiens University and Hospital, Amiens, France, 7Lithuanian University of Health Sciences, Kaunas, Lithuania, 8Hospital de São João, Porto, Portugal, 9Moscow Regional Research Clinical Institute, Moscow, Russian Federation, 10Tampere University Hospital, Tampere, Finland, 11Imperial College London, London, UK, 12Herlev University Hospital, Herlev, Denmark, 13State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Moldova, Republic of, 14Azienda Ospedaliera di Padova, Padova, Italy, 15Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 16Morgagni Hospital, Forli, Italy, 17Careggi Regional Referral Center for Inflammatory Bowel Disease, Florence, Italy, 18University Hospital, Ioannina, Greece, 19Charles University, Prague, Czech Republic, 20National Hospital of the Faroe Islands, Torshavn, Faroe Islands, 21Herning Hospital, Herning, Denmark, 22Mater Dei Hospital, Msida, Malta, 23Tartu University Hospital, Tartu, Estonia, 24University of Medicine ‘Victor Babes’, Timisoara, Romania, 25American Gastroenterology center, Nicosia, Cyprus, 26Slagelse Hospital, Department of medicine, Denmark, 27Regional Hospital of Viborg, Viborg, Denmark, 28Örebro University, Örebro, Sweden, 29Hull and East Yorkshire NHS Trust, Hull, UK, 30Aarhus University Hospital, Aarhus, Denmark

OP16: A randomised, multi-centre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of mild-to-moderate ulcerative colitis: efficacy results

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Bloom*1, T. Iqbal2, C. Nwokolo3, M. Smith4, D. O’Donoghue5, J. Hall6, B. Dzyngel6

1University College London Hospitals, London, UK, 2Queen Elizabeth Hospital Birmingham, Birmingham, UK, 3University Hospital Coventry and Warwickshire, Coventry, UK, 4Shrewsbury and Telford Hospital, Shrewsbury, UK, 5St Vincent’s University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 6Sublimity Therapeutics, Solana Beach, USA

OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Huang1, H. Irizar2, R. Kosoy3, W-m. Song3, A. Dinarzo3, K. Hao3, J. Rogers4, A. Atreja4, M. Mahajan3, A. Stojmirovic5, J. Perrigoue5, C. Brodmerkel5, S. Plevy5, J. Friedman5, J-F. Colombel4, M. Dubinsky4, B. Sands4, E. Schadt3, A. Kasarskis3, B. Losic3, C. Argmann3, M. Suarez-Farinas1,3

1Icahn School at Mount Sinai, Department of Population, Health Science and Policy, New York, USA, 2University College of London, London, UK, 3Icahn School at Mount Sinai, Department of Genetics and Genomic Science, New York, USA, 4Icahn School at Mount Sinai, Department of Medicine, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York City, USA, 5Janssen Research and Development, Janssen Biotech, Johnson and Johnson, Spring House, USA

OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Assa*1, M. Matar2, D. Turner3, E. Broide4, B. Weiss5, O. Ledder6, A. Guz Mark2, F. Rinawi2, S. Cohen7, C. Topf Olivestone8, R. Shaoul9, B. Yerushalmi10, R. Shamir2

1Schneider Children’s Hospital, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 2Schneider Children’s medical Center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 3Shaare Zedek Medical Center, Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, 4Assaf Harofeh, Pediatric Gastroenterology, Zerifin, Israel, 5Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel, 6Shaare Zedek Medical Center, Pediatric Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, 7Tel Aviv Medical Center, Pediatric Gastroenterology, Tel-Aviv, Israel, 8Kaplan Medical Center, Pediatric Gastroenterology, Rehovot, Israel, 9Rambam Medical center, Pediatric Gastroenterology, Haifa, Israel, 10Soroka Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel

OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

Y. Haberman*1,2, R. Karns2, P. Dexheimer2, M. Schirmer3, T. Braun1, M. Collins2, A. Mo4, M. Rosen2, N. Gotman5, PROTECT Study group, S. Kugathasan6, T. D. Walters7, G. Gibson4, S. Davis Thomas5, C. Huttenhower8, R. J. Xavier9, J. S. Hyams10, L. A. Denson2

1Sheba Medical Center, Tel Hashomer, Israel, 2Cincinnati Children Hospital Medical Center, Cincinnati, USA, 3Broad Institute of MIT and Harvard University, Cambridge, USA, 4Georgia Institute of Technology, Atlanta, USA, 5University of North Carolina, Chapel Hill, USA, 6Emory University, Atlanta, USA, 7Hospital For Sick Children, Toronto, Canada, 8Harvard School of Public Health, Boston, USA, 9Broad Institute of MIT and Harvard University, Boston, USA, 10Connecticut Children’s Medical Center, Hartford, USA

OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Lewis*1, R. Jeffrey1, T. Kumagai1, C. J. Hawkey2, M. M. Clark2, M. Allez3, J. Satsangi4, G. Rogler5, A. Silver1, J. O. Lindsay6

1Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Genomics and Child Health, London, UK, 2Centre for Digestive Diseases, Queens Medical Centre, Nottingham, UK, 3Department of Gastroenterology, Hôpital Saint Louis, APHP, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité Unversity, Paris, France, 4Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK, 5Department of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland, 6Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, UK

OP21: ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Vermeire1, X. Hébuterne2, P. Napora3, M. Wisniewska-Jarosinska4, G. Kiss5, A. Bourreille6, Z. Przemysław7, J. Nitcheu8, P. Gineste8, J-M. Steens*8, H. Ehrlich8

1University Hospitals Leuven, Leuven, Belgium, 2CHU Nice Hopital Archet 2, Nice, France, 3Piotr Napora Centrum Badań Klinicznych Lekarze Sp.p., Wroclaw, Poland, 4SANTA FAMILIA, Centrum Badań, Profilaktyki i Leczenia, Lodz, Poland, 5Vasútegészségügyi Nonprofit Közhasznú Kft, Debrecen, Hungary, 6CHU Nantes Hotel Dieu, Nantes, France, 7KO-Med, Lublin, Poland, 8Abivax, Paris, France

OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Barnhoorn*1, L. Plug1, E. Muller - de Jonge1, E. Bos2, A. van der Meulen - de Jong1, H. Verspaget1, L. Hawinkels1

1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, The Netherlands, 2Leiden University Medical Center, Cell and Chemical Biology, Leiden, The Netherlands

OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal models

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Shin*1, N. Ha1, D. Bae1, D-h. Suh1, J-y. Baek1, J. H. Jun1, Y. J. Lee1, Y. I. Choi1, K. H. Ryu1, G. S. Youn2, J. Park2, S-M. Lee3, S-k. Seo3, J. W. Lee4, J. S. Kim4,5

1Research Institute, Chong Kun Dang Pharmaceutical Corporation, Yongin, South Korea, 2Hallym University, Department of Biomedical Science, Chuncheon, South Korea, 3Inje University College of Medicine, Department of Microbiology and Immunology, Gimhae, South Korea, 4Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 5Seoul National University Hospital Healthcare System Gangnam Center, Department of Internal Medicine and Healthcare Research Institute, Seoul, South Korea

OP24: Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Fumery*1, L. Peyrin-biroulet2, S. Nancey3, R. Altwegg4, P. Veyrard5, G. Bouguen6, S. Viennot7, F. Poullenot8, J. Filippi9, A. Buisson10, A. Bozon11, C. Gilletta12, F. Brazier13, L. Pouillon2, B. Flourié14, L. Boivineau4, L. Siproudhis6, D. Laharie8, X. Roblin15, X. Treton11

1Amiens University Hospital, Gastroenterology, AMIENS (80000), France, 2Nancy University Hospital, Gastroenterology, Nancy, France, 3Lyon University Hospital, Lyon, France, 4Montpellier University Hospital, Gastroenterology, Montpellier, France, 5Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France, 6Rennes University Hospital, Gastroenterology, Rennes, France, 7Caen University Hospital, Gastroenterology, Caen, France, 8Bordeaux University Hospital, Gastroenterology, Bordeaux, France, 9Nice University Hospital, Gastroenterology, Nice, France, 10Clermont-Ferrand, Gastroenterology, Clermont-Ferrand, France, 11Hopital Beaujon, Gastroenterology, Clichy, France, 12Toulouse University Hospital, Gastroenterology, Toulouse, France, 13Amiens University Hospital, Gastroenterology, Amiens, France, 14Lyon University Hospital, Gastroenterology, Lyon, France, 15Saint Etienne University Hospital, Gastroenterology, Saint-Etienne, France

OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Dreesen*1, F. Baert2, D. Laharie3, P. Bossuyt4, Y. Bouhnik5, A. Buisson6, G. Lambrecht7, E. Louis8, B. Oldenburg9, B. Pariente10, M. Pierik11, C. J. van der Woude12, G. D’Haens13, S. Vermeire14,15, A. Gils1

1University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2AZ Delta, Department of Gastroenterology, Roeselare, Belgium, 3Hôpital Haut-Lévêque, Service d’Hépato-gastroentérologie et Oncologie Digestive, Bordeaux, France, 4Imelda General Hospital, IBD Clinic, Bonheiden, Belgium, 5Beaujon Hospital, APHP, Paris Diderot University, Department of Gastroenterology, Clichy, France, 6Estaing University Hospital, Department of Gastroenterology, Clermont-Ferrand, France, 7AZ Damiaan, Department of Gastroenterology, Oostende, Belgium, 8Liège University Hospital, Department of Gastroenterology, Liège, Belgium, 9University Medical Centre, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands, 10Huriez Hospital, Lille 2 University, Department of Gastroenterology and Hepatology, Lille, France, 11University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands, 12Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 13Academic Medical Centre, Department of Gastroenterology, Amsterdam, The Netherlands, 14University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 15University of Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Vermeire1, J-F. Colombel2, B. G. Feagan3, W. J. Sandborn4, B. E. Sands2, S. Danese5, G. D’Haens6, R. Panaccione7, D. T. Rubin8, I. Shafran9, A. Parfionovas10, R. Rogers*10, R. A. Lirio10, E. V. LoftusJr11

1University Hospitals Leuven, Leuven, Belgium, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3Western University, London, Canada, 4University of California San Diego, La Jolla, USA, 5Humanitas University, Milan, Italy, 6Academic Medical Centre, Amsterdam, The Netherlands, 7University of Calgary, Calgary, Canada, 8University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, USA, 9Shafran Gastroenterology Research Center, Winter Park, USA, 10Takeda Pharmaceuticals, Cambridge, USA, 11Mayo Clinic College of Medicine, Rochester, USA

OP27: High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

V. van Unen1, N. Li1, T. Abdelaal2,3, Y. Kooy-Winkelaar1, L. Ouboter*1,4, G. Beyrend1, T. Höllt3,6, L. Mearin7, A. Witte8, H. Escher9, B. Lelieveldt10,11, A. van der Meulen - de Jong4, F. Koning1

1Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden, The Netherlands, 2Delft University of Technology, Delft Bioinformatics Lab, Delft, The Netherlands, 3Leiden University Medical Center, Leiden Computational Biology Center, Leiden, The Netherlands, 4Leiden University Medical Center, Department of Gastroenterology, Leiden, The Netherlands, 6Delft University of Technology, Computer Graphics and Visualization, Delft, The Netherlands, 7Leiden University Medical Center, Department of Paediatrics, Leiden, The Netherlands, 8Alrijne Hospital, Department of Gastroenterology, Leiderdorp, The Netherlands, 9Erasmus University Medical Center, Department of Paediatric Gastroenterology, Rotterdam, The Netherlands, 10Delft University of Technology, Pattern Recognition and Bioinformatics Group, Delft, The Netherlands, 11Leiden University Medical Center, Department of LKEB Radiology, Leiden, The Netherlands

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 182 ()